
Bristol to Invest Up to $11.1 Billion in BioNTech Cancer Partnership
Bristol-Myers Squibb will pay BioNTech up to $11.1 billion to license a new cancer immunotherapy, marking a significant move in the competitive oncology market aiming to expand immune-based treatments, with the deal including upfront payments, milestone payments, and shared development costs.